InBrain Neuroelectronics announced today that it entered into a know-how collaboration agreement with Mayo Clinic.
The collaboration aims to accelerate the development and commercialization of the InBrain precision BCI-Tx brain-computer interface (BCI) for patients with unmet needs in neurological-related disorders.
Under the collaboration, InBrain and Mayo intend to work together on a non-exclusive know-how exchange to engage in hands-on evaluation of InBrain’s investigational BCI-Tx platform in IRB-approved settings. The company hopes to accelerate high-quality evidence generation as it advances its platform.
“Our goal is to translate the unique performance of graphene and AI to deliver benefits for patients and clinicians,” said Carolina Aguilar, CEO and co-founder, InBrain Neuroelectronics. “With Mayo Clinic’s clinical know-how, alongside other leading U.S. and European centers, we seek to validate our platform in real-world workflows, accelerate evidence generation, and move responsibly toward patient-focused BCI therapeutics.”
More about expansion plans for InBrain
As the Barcelona-based company works with Mayo Clinic, it also seeks to establish a firmer footprint in the U.S. It formed a U.S. subsidiary to collaborate with leading academic centers. The company plans to open locations in Boston and on the West Coast. InBrain plans for its global headquarters and R&D to remain in Spain.
InBrain plans to make the initial Boston office its hub for U.S.-based clinical trials. It hopes to build the foundation for commercialization and therapeutic expansion of its BCI-Tx beyond Parkinson’s disease. The company also plans to advance scalable manufacturing processes for its graphene-based BCI to enable broader clinical and commercial adoption worldwide.
The company’s BCI technology integrates intelligent computing and graphene-based materials to decode and modulate real-time brain activity. InBrain already has positive first-in-human clinical results for its technology, reported in July.
Graphene, a two-dimensional material made of a lattice of carbon atoms, is stronger than steel and thinner than a human hair. It utilizes a combination of electrical and mechanical properties. InBrain says its neural platform enables ultra-high signal resolution, using machine learning software to decode therapy-specific biomarkers. It delivers highly focused, adaptive neuroelectronic therapy that re-balances pathological neural networks.
Future applications of the BCI technology could include neuromodulation for Parkinson’s, stroke rehabilitation, epilepsy and potentially neuropsychiatric disorders.
In 2023, InBrain received FDA breakthrough device designation for its graphene-neural platform as an adjunctive therapy for treating Parkinson’s disease. It kicked off the first-in-human study last fall. The company also added $50 million in a Series B funding round a month later. It reports a total of $124 million raised to date.
